🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction

RecruitingNAAges 50 Years - anyAllThe Fourth Affiliated Hospital of Zhejiang Univer…
NCT07353502 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities. Current research has found that in the early stages of the disease, synaptic connections between brain nerve cells become abnormal, but the specific cause is still unclear. Investigators' previous research discovered that in the brains of diseased mice, certain special substances (the miR 342 5p/AnkG-mediated pathway) might be related to this abnormality, and these substances can be detected in both blood and cerebrospinal fluid. Therefore, investigators want to further explore the specific mechanisms of abnormal nerve cell connections, seek biomarkers for early detection of the disease, and provide new ideas for early diagnosis in the future.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Inclusion criteria for AD group: 1. Meet the diagnostic criteria for "probable AD dementia" established by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) 2. MMSE score between 0-23 points, Clinical Dementia Rating (CDR) score ≥0.5 points, Hachinski Ischemic Score \<4 points 3. Brain MRI showing bilateral temporal lobe and hippocampal atrophy 4. Age ≥50 years Inclusion criteria for control group: 1. Healthy subjects with age matched to the AD group 2. Normal cognitive function and good activities of daily living 3. No dementia patients among first-degree relatives 4. Negative brain MRI and neurological examination Exclusion Criteria: 1. Dementia or cognitive impairment caused by other diseases 2. History of substance abuse 3. Progressive primary aphasia 4. Previous traumatic brain injury 5. Patients with comorbid depression, schizophrenia, or severe diseases of the cardiovascular, hepatic, renal, or hematological systems 6. Impaired consciousness and inability to cooperate 7. Other conditions unsuitable for inclusion
💊

What it tests

  • Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.
📍

Where

1 site
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Yiwu, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy